Amgen Inc. (AMGN)
NASDAQ: AMGN · Biotechnology · Thousand Oaks, CA
Our rating: Neutral
Neutral reaffirmed at $460.28, moderate conviction, November 5, 2026.
Breaks if: The Neutral call turns Cautious if revenue growth decelerates to below 5% year-over-year or the free cash flow margin falls below 18% (against the current ~22%) in any reported period — either signals the franchise is losing momentum at a multiple that cannot absorb it. It turns Positive if revenue growth sustains above 15% for two consecutive reported quarters, indicating the new-product cycle is running materially ahead of what the current price already reflects.
Key figures
| Market value | $235.6B |
|---|---|
| Revenue, last 12 months | $38.9B |
| Net income, last 12 months | $9.4B |
| Free cash flow, last 12 months | $9.6B |
| Price to earnings | 25.1× |
| Free cash flow yield | 4.1% |
| Dividend yield | 2.9% |
| Operating margin | 32.4% |
| Return on equity | 78.4% |
| Beta to the S&P 500 | 0.47 |
| Volatility, annualized | 27.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $10.4B | 8.5% | $7.08 | $3.7B |
| June 30, 2026 | $10.1B | 9.5% | $4.37 | $3.5B |
| March 31, 2026 | $8.6B | 5.8% | $3.34 | $1.5B |
| December 31, 2025 | $9.9B | 8.6% | $2.46 | $961M |
| September 30, 2025 | $9.6B | 12.4% | $5.93 | $4.2B |
| June 30, 2025 | $9.2B | 9.4% | $2.65 | $1.9B |
| March 31, 2025 | $8.1B | 9.4% | $3.20 | $980M |
| December 31, 2024 | $9.1B | 10.9% | $1.16 | $4.4B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $10.7B: Claude 62%, Gemini 88%, Mistral 70%
- Diluted earnings per share are at least $2.46: Claude 60%, Gemini 98%, Mistral 90%
- Free cash flow for the quarter is at least $0.96B: Claude 72%, Gemini 97%, Mistral 92%
17 ledger entries and 41 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.